Patents by Inventor Curt Dvorak

Curt Dvorak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240116930
    Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    Type: Application
    Filed: October 18, 2023
    Publication date: April 11, 2024
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Manuel Jesus ALCAZAR VACA, Jose Lgnacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De Angelis, Curt A Dvorak, Christine F. Gelin, Michael A. Letavic, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson
  • Patent number: 11820770
    Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    Type: Grant
    Filed: January 14, 2022
    Date of Patent: November 21, 2023
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Manuel Jesus Alcazar Vaca, Jose Ignacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De Angelis, Curt A. Dvorak, Christine F. Gelin, Michael A. Letavic, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson
  • Publication number: 20230151006
    Abstract: Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
    Type: Application
    Filed: October 14, 2022
    Publication date: May 18, 2023
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Afton HISCOX, Akinola SOYODE-JOHNSON, Brice STENNE, Christa CHROVIAN, Christine GELIN, Andrew SAMANT, Michael A. LETAVIC, Curt DVORAK
  • Patent number: 11618750
    Abstract: Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: April 4, 2023
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Afton Hiscox, Akinola Soyode-Johnson, Brice Stenne, Christa Chrovian, Christine Gelin, Andrew Samant, Michael A. Letavic, Curt Dvorak
  • Publication number: 20230045960
    Abstract: Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
    Type: Application
    Filed: September 12, 2022
    Publication date: February 16, 2023
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Afton HISCOX, Brice STENNE, Christa CHROVIAN, Christine GELIN, Andrew SAMANT, Michael A. LETAVIC, Curt DVORAK
  • Patent number: 11530210
    Abstract: Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: December 20, 2022
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Afton Hiscox, Brice Stenne, Christa Chrovian, Christine Gelin, Andrew Samant, Michael A. Letavic, Curt Dvorak
  • Publication number: 20220324860
    Abstract: Substituted pyrazolo[4,3-b]pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
    Type: Application
    Filed: June 12, 2020
    Publication date: October 13, 2022
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Afton HISCOX, Brice STENNE, Christine GELIN, Andrew SAMANT, Jessica WALL, Michael A. LETAVIC, Curt DVORAK
  • Publication number: 20220315590
    Abstract: Substituted PYRAZOLO-PYRAZINES as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
    Type: Application
    Filed: June 12, 2020
    Publication date: October 6, 2022
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Curt DVORAK, Heather COATE
  • Patent number: 11447503
    Abstract: Pyridine carbamates, pharmaceutical compositions containing pyridine carbamates, and uses of the pyridine carbamates and pharmaceutical compositions for modulating GluN2B receptors and for treating diseases, disorders, and medical conditions mediated by GluN2B receptor activity.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: September 20, 2022
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Christine Gelin, Heather Coate, Brice Stenne, Curt Dvorak
  • Publication number: 20220274984
    Abstract: Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
    Type: Application
    Filed: February 9, 2022
    Publication date: September 1, 2022
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Afton HISCOX, Brice STENNE, Christa CHROVIAN, Christine GELIN, Andrew SAMANT, Michael A. LETAVIC, Curt DVORAK
  • Publication number: 20220213095
    Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    Type: Application
    Filed: January 14, 2022
    Publication date: July 7, 2022
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Manuel Jesus ALCAZAR VACA, Jose Ignacio ANDRES GIL, Christa C. CHROVIAN, Heather R. COATE, Meri DE ANGELIS, Curt A. DVORAK, Christine F. GELIN, Michael A. LETAVIC, Brad M. SAVALL, Akinola SOYODE-JOHNSON, Brice M. STENNE, Devin M. SWANSON
  • Patent number: 11225478
    Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    Type: Grant
    Filed: June 25, 2020
    Date of Patent: January 18, 2022
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Manuel Jesus Alcazar Vaca, Jose Ignacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De angelis, Curt A. Dvorak, Christine F. Gelin, Michael A. Letavic, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson
  • Patent number: 11214563
    Abstract: Substituted PYRAZOLO-PYRAZINES as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: January 4, 2022
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Curt Dvorak, Heather Coate
  • Patent number: 11161846
    Abstract: Substituted pyrazolo[4,3-b]pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: November 2, 2021
    Assignee: JANSSEN PHARMACEUTICA NV
    Inventors: Afton Hiscox, Brice Stenne, Christine Gelin, Andrew Samant, Jessica Wall, Michael A. Letavic, Curt Dvorak
  • Publication number: 20210017169
    Abstract: Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
    Type: Application
    Filed: June 12, 2020
    Publication date: January 21, 2021
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Afton HISCOX, Brice STENNE, Christa CHROVIAN, Christine GELIN, Andrew SAMANT, Michael A. LETAVIC, Curt DVORAK
  • Publication number: 20210017168
    Abstract: Substituted Pyrazolo-pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
    Type: Application
    Filed: June 12, 2020
    Publication date: January 21, 2021
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Afton HISCOX, Akinola SOYODE-JOHNSON, Brice STENNE, Christa CHROVIAN, Christine GELIN, Andrew SAMANT, Michael A. LETAVIC, Curt DVORAK
  • Publication number: 20200392154
    Abstract: Pyridine carbamates, pharmaceutical compositions containing pyridine carbamates, and uses of the pyridine carbamates and pharmaceutical compositions for modulating GluN2B receptors and for treating diseases, disorders, and medical conditions mediated by GluN2B receptor activity.
    Type: Application
    Filed: June 12, 2020
    Publication date: December 17, 2020
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Christine GELIN, Heather COATE, Brice STENNE, Curt DVORAK
  • Publication number: 20200392130
    Abstract: Substituted pyrazolo[4,3-b]pyridines as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
    Type: Application
    Filed: June 12, 2020
    Publication date: December 17, 2020
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Afton HISCOX, Brice STENNE, Christine GELIN, Andrew SAMANT, Jessica WALL, Michael A. LETAVIC, Curt DVORAK
  • Publication number: 20200392113
    Abstract: Substituted PYRAZOLO-PYRAZINES as GluN2B receptor ligands. Such compounds may be used in GluN2B receptor modulation and in pharmaceutical compositions and methods for the treatment of disease states, disorders, and conditions mediated by GluN2B receptor activity.
    Type: Application
    Filed: June 12, 2020
    Publication date: December 17, 2020
    Applicant: JANSSEN PHARMACEUTICA NV
    Inventors: Curt DVORAK, Heather COATE
  • Publication number: 20200325138
    Abstract: The present invention is directed to compounds of Formulas (I, IIa and IIb): The invention also relates to pharmaceutical compositions comprising compounds of Formulas (I, IIa and IIb). Methods of making and using the compounds of Formulas (I, IIa and IIb) are also within the scope of the invention.
    Type: Application
    Filed: June 25, 2020
    Publication date: October 15, 2020
    Inventors: Manuel Jesus Alcazar Vaca, Jose Ignacio Andres Gil, Christa C. Chrovian, Heather R. Coate, Meri De angelis, Curt A. Dvorak, Christine F. Gelin, Michael A. Letavic, Brad M. Savall, Akinola Soyode-Johnson, Brice M. Stenne, Devin M. Swanson